Core Viewpoint - Pulmatrix and Cullgen have agreed to waive the "No Solicitation" clause in their Merger Agreement to explore alternative transactions while seeking approval from the China Securities Regulatory Commission (CSRC) for their merger [1][2]. Merger Agreement Details - The Merger Agreement between Pulmatrix and Cullgen was signed on November 13, 2024, and amended on April 7, 2025 [3]. - The Form S-4 filing related to the merger was declared effective in May 2025, and stockholders approved the merger in June 2025 [2][4][5]. - The closing of the merger is contingent upon Nasdaq's approval and CSRC's approval [5]. Financial Position - As of September 30, 2025, Pulmatrix had a total cash and cash equivalents balance of $4.8 million, which is expected to fund operations into at least the fourth quarter of 2026 [6]. Clinical Assets and Technology - Pulmatrix's proprietary iSPERSE™ technology is designed for inhaled therapeutic products aimed at treating migraine and respiratory diseases [13]. - The company has a pipeline that includes PUR3100, a Phase 2-ready asset for acute migraine treatment, and PUR1800, a Narrow Spectrum Kinase Inhibitor for chronic obstructive pulmonary disease [8][16]. - Pulmatrix's patent portfolio related to iSPERSE™ includes approximately 146 granted patents and about 50 pending applications [9]. Collaboration and Future Development - Pulmatrix is collaborating with Cipla on the development of PUR1900, an inhaled formulation of itraconazole, which is undergoing clinical trials in India [16].

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profileWTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trialAdditional Phase 1/1b data update for WTX-124 and completion ...

BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence stu ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmacokinetics for ...

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical co ...

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte immunoGlobUlin ...

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte immunoGlobUlin ...

Core Viewpoint - Appili Therapeutics Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of C$177,500 to support its drug development efforts for infectious diseases and biodefense [1][4]. Group 1: Private Placement Details - The private placement involved the issuance of 7,100,000 units at a price of C$0.025 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant, subject to shareholder approval, will allow the holder to acquire one common share at a price of C$0.05 for 36 months from the closing date [2][3]. - The company has also paid C$14,200 to finders and issued 568,000 broker warrants, which will allow the purchase of common shares at a price of not less than C$0.02834 for 24 months, also subject to shareholder approval [4][5]. Group 2: Future Plans and Use of Proceeds - The net proceeds from the private placement will primarily be used for working capital and to fund the development of certain product candidates [4]. - A secondary tranche of the private placement is planned to close in December 2025 [6]. Group 3: Company Overview - Appili Therapeutics is focused on developing therapies for life-threatening infections, with a portfolio that includes an FDA-approved treatment for antimicrobial resistant infections and a vaccine candidate for tularemia [7]. - The company aims to strategically develop a pipeline of novel therapies to address urgent infections with unmet needs, positioning itself at the forefront of the global fight against infection [7].

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide fo ...

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Cambridge, Massachusetts, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines ...